Sacubitril/valsartan:upstream treatment of atrial fibrillation
Treatment of atrial fibrillation(AF)includes antiarrhythmic drug therapy and radiofrequency ablation surgery.Most AF patients receiving drug therapy have a high recurrence rate,and the long-term recurrence rate is not ideal in AF patients treated with radiofrequency ablation.Therefore,the upstream treatment of AF has been increasingly concerned.Upstream medication aims to reverse or prevent the pathophysiological process leading to atrial remodeling,which is conducive to reducing the onset or recurrence of AF.The effect of sacubitril/valsartan on reversing atrial remodeling in heart failure has been well recognized,presenting the theoretical efficacy on reducing the occurrence of atrial fibrillation.However,its specific mechanism is not clear,and direct clinical evidences are lacked.Through literature review on domestic and foreign literatures reporting the treatment of AF by sacubitril/valsartan and the latest research evidence,this paper reviews the upstream treatment of AF by sacubitril/valsartan.
万方数据
维普
